Development of prophylactic and therapeutic vaccines against hepatitis C virus.

about

Griffithsin has antiviral activity against hepatitis C virus Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.Managing pediatric hepatitis C: current and emerging treatment options.HCV animal models: a journey of more than 30 years.

P2860

Q35363633-5FBFD6DF-6775-438E-8E04-F2B2A964D094 Q37235541-04F1A3A8-1F1B-473A-AB00-3A7066D296EE Q37316248-79805909-0DB7-42BA-AB59-79A8EE252088 Q37945172-989241F8-7039-4834-B4EB-FC86815D2017

P2860

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

Item

http://www.wikidata.org/entity/Q36198667

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@ast

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@en

type

Item

label

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@ast

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@en

prefLabel

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@ast

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@en

P1476

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

@en

P2860

Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon.

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.

Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mi

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection.

P304

351-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14760584.4.3.351

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Geert Leroux-Roels

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16026249

http://www.w3.org/2001/XMLSchema#string

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

about

P2860

P2860

Development of prophylactic and therapeutic vaccines against hepatitis C virus.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698